Preview of a life‑sciences presentation on developing anti-inflammatory and anti‑fibrotic therapies for heart disease at an investor summit.
Key Takeaways
- CardiolRx modulates inflammasome activation implicated in inflammation and fibrosis in cardiac diseases
- MAVERIC program is evaluating CardiolRx in pivotal Phase III trials for recurrent pericarditis
- Company is also developing CRD-38, a subcutaneous candidate targeting inflammatory heart disease and heart failure